Therapeutic agents and uses thereof

Use of an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein in the manufacture of a medicament for the treatment of prostate cancer.

A method for the treatment of prostate cancer in a patient, the method comprising the step of administering a therapeutically effective amount of an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein.

The agent, use, or method of any preceding claim, wherein the binding moiety has specificity for a human kallikrein protein.

The agent, use, or method of any preceding claim, wherein the binding moiety has specificity for a kallikrein selected from the group consisting of prostate-specific antigen (PSA;

• hk3, human kallikrein gene 3) and human glandular kallikrein (hK2).

The agent, use, or method of any preceding claim, wherein the binding moiety has specificity for PSA.

The agent, use, or method of any preceding claim, wherein the binding moiety competes for binding to PSA with an antibody selected from the group consisting of PSA30, 4D4, 5C3, and 5A10, and an antigen-binding fragment thereof.

The agent, use, or method of any preceding claim, wherein the binding moiety comprises one or more complementarity determining regions (CDRs) of an antibody selected from the group consisting of PSA30, 4D4, 5C3, and 5A10.

The agent, use, or method of any preceding claim, wherein the binding moiety comprises or consists of an antibody selected from the group consisting of PSA30, 4D4, 5C3, and 5A10, and antigen-binding fragments thereof.

The agent, use, or method of any preceding claim wherein the agent further comprises a therapeutic moiety, such as a cytotoxic moiety.

The agent, use, or method of any preceding claim, wherein the agent further comprises a detectable moiety.

The agent, use, or method of any of any preceding claim wherein the agent further comprising a moiety for increasing the in vivo half-life of the agent.

The agent, use, or method of any preceding claim wherein the prostate cancer to be treated is non-localised (i.e., disseminated) prostate cancer.

The agent, use, or method of any preceding claim wherein the prostate cancer to be treated is metastatic prostate cancer, optionally micrometastatic prostate cancer.

The agent, use, or method of any preceding claim wherein the patient has prostate cancer and is less than 70, 65, 60, 55, 50, 45, 40 or less years old at the time of diagnosis of prostate cancer and/or at the time of treatment.

The agent, use, or method of any preceding claim wherein the patient is characterised in that a family member, such as a father or brother, has been previously been diagnosed with prostate cancer.

The agent, use, or method of any preceding claim wherein the prostate cancer to be treated is castration-resistant prostate cancer (CRPC).

A therapeutic agent comprising a binding moiety with specificity for a kallikrein protein and a therapeutic moiety, as defined in any preceding claim, that is suitable for the treatment of prostate cancer.

A pharmaceutical composition comprising a therapeutically effective amount of an agent as defined in any one of the preceding claims and a pharmaceutically-acceptable diluent, carrier or excipient.

An agent for use in medicine substantially as described herein with reference to the description.

A pharmaceutical composition substantially as described herein with reference to the description.

Use of an agent substantially as described herein with reference to the description.

A method of treatment as substantially described herein with reference to the description.

A kit substantially as defined herein with reference to the description.